A national cross-sectional study for poliovirus seroprevalence in the Republic of Korea in 2012: implication for deficiency in immunity to polio among middle-aged people

BMC Infectious Diseases

Research Article

Yong-Seok Jeong¹  Kwangsook Park²  Young Joon Park²  Geun-Ryang Bae²  Yunhyung Kwon³  Ji-Yeon Hyeon⁴  Seoyeon Hwang⁴  Somin Lee⁴  Sang Won Lee⁴  Hye-Jin Kim⁵ 

[1] Department of Biology Graduate School, Kyung Hee University, 130-701, Seoul, Dongdaemon-gu, Republic of Korea;Division of Vaccine Preventable Disease Control and Prevention, Center for Infectious Diseases Control, Korea Centers for Disease Control and Prevention, Osong-eup, 363-951, Cheongju, Chungcheongbuk-do, Republic of Korea;Division of Vaccine Preventable Disease Control and Prevention, Center for Infectious Diseases Control, Korea Centers for Disease Control and Prevention, Osong-eup, 363-951, Cheongju, Chungcheongbuk-do, Republic of Korea;Current Address: Division of HIV/AIDS and TB Control, Center for Infectious Diseases Control, Korea Centers for Disease Control and Prevention, Osong-eup, 363-951, Cheongju, Chungcheongbuk-do, Republic of Korea;WHO Polio National Reference Laboratory, Division of Vaccine Research, Center for Infectious Diseases, Korea National Institutes of Health, Korea Centers for Disease Control and Prevention, Osong-eup, 363-951, Cheongju, Chungcheongbuk-do, Republic of Korea;WHO Polio National Reference Laboratory, Division of Vaccine Research, Center for Infectious Diseases, Korea National Institutes of Health, Korea Centers for Disease Control and Prevention, Osong-eup, 363-951, Cheongju, Chungcheongbuk-do, Republic of Korea;Department of Biology Graduate School, Kyung Hee University, 130-701, Seoul, Dongdaemon-gu, Republic of Korea;

关键词: Poliovirus;    Neutralization antibody;    Seroprevalence;    Inactivated polio vaccine;   

DOI  :  10.1186/s12879-015-0894-z

 received in 2014-12-01, accepted in 2015-03-12,  发布年份 2015

来源: Springer

【 摘 要 】

BackgroundA worldwide poliomyelitis eradication program was initiated in 1988; however, strains of wild poliovirus (WPV) are still endemic in some countries. Until WPV transmission is eradicated globally, importation and outbreaks of WPV are alarming possibilities. This study is the first report to document the polio immunity after 2004, when an inactivated polio vaccine (IPV) was introduced in the Republic of Korea.MethodsA total of 745 serum samples from randomly selected patients ranging from 6 to 84 years of age were used for neutralization tests, performed in the World Health Organization polio national reference laboratory.ResultsAmong the 745 tested sera, 439 (58.9%) were seropositive and 19 (2.6%) were seronegative to all PV serotypes. In all age groups, PV3 showed the lowest level of seroprevalence, at 509 cases (68.3%), compared to 616 (82.7%) for PV1 and 685 (91.9%) for PV2. In the 6–10-year age group, which included IPV-immunized children, the highest seropositive rate was observed and the difference in seroprevalence between PV3 and other serotypes was the lowest compared to the other age groups immunized with oral PV vaccines (OPV). In addition, the seronegative rates of all three PV types in children aged 6–10 in this study were found to be lower than those in OPV-immunized children reported in a previous study from the Republic of Korea. Meanwhile, middle-aged subjects (41–60 years) had the lowest seroprevalence and geometric mean titer.ConclusionsThis study indicates a deficiency in immunity to PV in middle-aged individuals, and low seroprevalence to PV3 in all age groups. In addition, due to the ongoing risk of importing PV, middle-aged people should consider PV vaccination before visiting a PV-endemic country. Our findings provide data to assist those involved in deciding future national polio vaccination strategies for the maintenance of a polio-free status in Korea.

【 授权许可】

Unknown   
© Kim et al.; licensee BioMed Central. 2015. This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.